scholarly journals Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial

2021 ◽  
Author(s):  
Li Ni ◽  
Zheng Wen ◽  
Xiaowen Hu ◽  
Wei Tang ◽  
Haisheng Wang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Multicenter Clinical Trial ◽  
Open Label

Effects of benazepril in the treatment of feline hypertrophic cardiomyopathy Results of a prospective, open-label, multicenter clinical trial

1999 ◽  
Vol 1 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Christophe N. Amberger ◽  
Olivier Glardon ◽  
Tony Glaus ◽  
Angelika Hörauf ◽  
Jonathan N. King ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Hypertrophic Cardiomyopathy ◽  
Multicenter Clinical Trial ◽  
Open Label

scholarly journals Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome

2017 ◽  
Vol 181 ◽  
pp. 102-111.e5 ◽  
Author(s):  
Beth A. Carter ◽  
Valeria C. Cohran ◽  
Conrad R. Cole ◽  
Mark R. Corkins ◽  
Reed A. Dimmitt ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Short Bowel Syndrome ◽  
Multicenter Clinical Trial ◽  
Open Label ◽  
Short Bowel

The efficacy of topical prophylactic antiglaucoma therapy in primary closed angle glaucoma in dogs: a multicenter clinical trial

2000 ◽  
Vol 36 (5) ◽  
pp. 431-438 ◽  
Author(s):  
PE Miller ◽  
GM Schmidt ◽  
SJ Vainisi ◽  
JF Swanson ◽  
MK Herrmann
Keyword(s):  
Clinical Trial ◽  
Topical Corticosteroid ◽  
Untreated Control ◽  
Multicenter Clinical Trial ◽  
Open Label ◽  
Dosing Schedule ◽  
Fellow Eye ◽  
Closed Angle

The ability of either 0.5% betaxolol (1 drop topically, bid; n=31) or a combination of 0.25% demecarium bromide and a topical corticosteroid (gentamicin/betamethasone) (DB/GB; 1 drop of each topically, sid; n=55) to prevent glaucoma in the fellow eye of dogs with unilateral, primary closed angle glaucoma (PCAG) was investigated in a multicenter, open-label, clinical trial. Untreated control dogs (n=20) developed glaucoma significantly sooner (median, eight mos; p less than 0.001) than dogs treated either with DB/GB (median, 31 mos) or betaxolol (median, 30.7 mos). Although DB/GB and betaxolol equally delayed or prevented the onset of glaucoma in the second eye, a less frequent dosing schedule for DB/GB suggests demecarium bromide in combination with a topical corticosteroid may be preferable to betaxolol in preventing PCAG in dogs.

Sign in / Sign up

Export Citation Format

Share Document